U.S. Banks Stock News

If you are wondering whether Netskope at around US$8.47 is starting to look interesting on price, the key question is how that tag lines up with the underlying business value. The stock has been under pressure recently, with a 7 day return of a 6.6% decline, a 30 day return of a 29.5% decline, and a year to date return of a 49.9% decline. This naturally raises questions about whether sentiment has swung too far or not far enough. Recent news coverage has focused on Netskope as part of...

GRAIL (NasdaqGS:GRAL) has entered a new collaboration with Junction to integrate its Galleri multi cancer early detection test into Junction’s digital health infrastructure. The partnership is designed to broaden access to Galleri across digital health platforms and healthcare organizations by embedding the test into unified clinical and operational workflows. The collaboration focuses on streamlining ordering, results management, and complex workflow handling for both providers and patients...

Investors may be wondering whether Acadia Realty Trust is offering good value at its current price, or if the easier gains have already passed. The stock recently closed at US$20.37, with returns of 4.9% over the last week, a 1.6% decline over the last month, a 1.3% decline year to date, 14.3% over the last year, 74.9% over three years, and 23.6% over five years. Recent coverage has focused on Acadia as a retail focused REIT, with ongoing attention on how its portfolio and tenant mix...

If you are wondering whether Western Midstream Partners at around US$40.94 is still offering value, you are not alone. This article focuses on exactly that question. The unit price has moved by 2.1% over the last 30 days, with a 25.2% return over 1 year and a very large 217.2% return over 5 years. This naturally raises questions about how much value is already reflected in the current price. Recent news coverage has mainly centered on Western Midstream Partners as a key player in the US...

Wondering if Intercontinental Exchange at around US$161.97 is still a fair entry point or if the value story has already played out? This article focuses squarely on what the current price might imply. The stock has moved by 1.1% over the last 30 days and 5.6% over the past year, with a 56.5% return over 3 years and 44.1% over 5 years, which hints at a long track record that many investors will be weighing against today's valuation. Recent coverage has focused on Intercontinental Exchange as...

Investors may be wondering whether PACS Group at around US$35.97 is still offering value after its strong run, or if the easy gains are already behind it. The stock has moved 11.9% over the last 7 days and 5.3% over the last 30 days, while the 1 year return of 286.8% contrasts with a year to date return of a 9.0% decline. Recent attention on PACS Group has centered on its strong 1 year share price performance and the healthcare services segment it operates in. This has made the stock more...

If you are wondering whether Tetra Tech's current share price offers good value or if you might be overpaying for quality, this article walks through the key valuation checks that matter most. The stock last closed at US$30.85, with a 0.7% decline over 7 days, an 8.1% decline over 30 days, and an 8.3% decline year to date. The 1 year, 3 year, and 5 year returns sit at 6.2%, 7.2%, and 16.9% respectively. Recent price movements are occurring against a backdrop of ongoing investor interest in...

Prairie Operating Co. reported past full-year 2025 results on March 30, 2026, showing revenue of US$241.65 million versus US$7.94 million a year earlier and moving from a net loss of US$40.91 million to net income of US$32.05 million, alongside detailed production disclosure. Management also issued production and earnings guidance for 2026, targeting average daily output of 25,500–27,500 Boe/d and net income of US$55 million to US$65 million, highlighting how operational scale now ties...

Wondering if Oncolytics Biotech at US$1.04 is priced for its potential or already running ahead of itself? This article walks through what the numbers are actually saying about value. The stock shows mixed return figures, with a 7 day return of 8.3%, 30 day return of 2.0%, year to date return of 5.7%, a 1 year return of 108.0%, a 3 year return of 11.9% decline, and a 5 year return of 64.5% decline that some investors may see as a reset in expectations. Recent attention around Oncolytics...

BridgeBio Pharma (NasdaqGS:BBIO) reported long term data for acoramidis (Attruby) in transthyretin amyloid cardiomyopathy, showing sustained efficacy, safety and quality of life outcomes over several years. The company highlighted the role of early and continuous treatment for ATTR-CM patients, citing ongoing unmet medical needs with existing options. BridgeBio submitted a New Drug Application to the US FDA for BBP-418, supported by Phase 3 data in limb-girdle muscular dystrophy type...

Omnicell (OMCL) has been on investors’ radar after recent trading left the shares with a one-month return of about a 9% decline and a past three-month move of roughly a 30% decline. See our latest analysis for Omnicell. At a share price of US$35.47, Omnicell’s 7 day share price return of 3.9% contrasts with a 30 day share price return of about a 9% decline and a year to date share price return of about a 21% decline. The 1 year total shareholder return of 14.1% shows the effect of holding...

If you are wondering whether Vishay Intertechnology at around US$21.33 is still offering value after a strong run, you are not alone. The stock has posted returns of 14.8% over the last week, 23.2% over the last month, 39.5% year to date and 91.2% over the past year. This naturally raises questions about what is already priced in and how much risk you are now taking. Recent coverage has focused on Vishay Intertechnology's position within the broader electronics space and how investors are...

Artificial intelligence in healthcare is attracting fresh attention as investors weigh higher for longer inflation risks, volatile bond yields, and energy driven cost pressures. While many sectors are wrestling with rising input and financing costs, AI in healthcare is focused on accuracy, efficiency, and better patient outcomes, themes that can matter across economic cycles. This article highlights 3 stocks from the Transformative AI Healthcare Stocks screener, a focused way to look at...

Applied Digital (APLD) just posted its Q3 2026 numbers, reporting revenue of US$126.6 million and a basic EPS loss of US$0.36. Trailing twelve month revenue came in at US$319.3 million, alongside a basic EPS loss of US$0.46. Over recent quarters, the company’s revenue has moved from US$38.0 million in Q4 2025 to US$64.2 million in Q1 2026, US$161.7 million in Q2 2026 and now US$126.6 million in Q3 2026. Over the same period, quarterly basic EPS shifted from a loss of US$0.12 to a loss of...

In late March 2026, Cadre Holdings, Inc. filed a universal shelf registration to potentially issue common and preferred stock, debt securities, warrants, purchase contracts, and units. This broad capital-raising framework gives Cadre added financial flexibility that could support future initiatives but also raises questions about possible dilution and capital deployment priorities. Next, we’ll examine how this new capital-raising flexibility may influence Cadre Holdings’ earnings reset...

Rush Street Interactive (NYSE:RSI) reported recent insider stock sales by its Chief Legal Officer and Chief Financial Officer, carried out under prearranged 10b5-1 trading plans. The insider transactions come as the company continues to report strong fundamental performance, including better-than-expected quarterly results. RSI is also seeing considerable user growth in North American iCasino markets, which remains a key area of focus for the business. Rush Street Interactive operates...

A recent proposed 2027 US federal budget outlined sizeable spending cuts for health agencies, including a US$5.00 billion reduction for the National Institutes of Health, raising questions about future research funding across the healthcare ecosystem. For QuidelOrtho, the budget proposal has added another layer of uncertainty to an already pressured diagnostics landscape, where policy decisions can influence funding flows, customer priorities, and long-term demand for testing...

Recent commentary on Microvast Holdings highlights weak technical indicators and broad selling pressure across investor groups, pointing to a cautious market stance toward the battery maker. This deterioration in technical momentum contrasts with earlier expectations tied to Microvast’s advanced battery innovations and global capacity expansion plans. We’ll now examine how this bearish technical and sentiment backdrop interacts with Microvast’s longer-term investment narrative built around...

Consolidated Edison, Inc. has recently drawn attention as analysts grew more optimistic ahead of its 1st Quarter 2026 earnings release, scheduled for May 7, 2026, following a pattern of the company topping earnings estimates in recent quarters. This combination of a positive Earnings ESP and an upgraded Zacks Rank has reinforced the view that Consolidated Edison’s regulated utility operations may continue to surprise relative to consensus expectations. With this backdrop of analyst optimism...

EVERTEC, Inc. recently announced that its cloud-focused subsidiary, Nubity by Evertec, has been recognized as an AWS Premier Tier Partner, the highest level within the Amazon Web Services Partner Network for providers with proven expertise in deploying AWS-based solutions. This designation highlights EVERTEC’s efforts to deepen its cloud capabilities, potentially strengthening its role in complex digital transformations across Latin America and the Caribbean. Next, we will explore how...

If you are wondering whether Mach Natural Resources is attractively priced or not, the starting point is understanding what the current share price is actually giving you. The stock recently closed at US$12.35, with a 12.2% decline over the last 7 days and a 5.2% decline over the last 30 days, while still showing a 9.8% return year to date and a 9.3% return over the last year. Recent trading has been shaped by ongoing interest in the oil and gas sector and how investors weigh commodity price...

JD Bancshares (JDVB) just wrapped up FY 2025 with fourth quarter revenue of US$14.6 million and basic EPS of US$0.97, alongside trailing 12 month revenue of US$56.9 million and EPS of US$3.78, compared with FY 2024 trailing 12 month revenue of US$55.6 million and EPS of US$3.97. Over that same trailing 12 month window, net income moved from US$13.6 million in FY 2024 to US$13.0 million in FY 2025. This may prompt investors to focus on how margins and overall profitability quality shape the...

Constellation Brands (STZ) has just wrapped up FY 2026 with fourth quarter revenue of US$1,920.2 million and basic EPS of US$1.16. The latest trailing twelve month figures show revenue of US$9.1 billion and EPS of US$9.62. Over recent periods, quarterly revenue has ranged from US$1,920.2 million to US$2,515 million, with basic EPS between US$1.16 and US$3.40. This sets up a picture of earnings that now sit against a return to profitability on a trailing basis and margins that investors will...

If you are wondering whether Spectrum Brands Holdings at about US$80.22 is offering fair value or hiding a margin of safety, you are asking the right question. The stock has delivered returns of 8.8% over the last 7 days, 6.2% over 30 days, 33.6% year to date and 35.2% over the last year, which naturally raises questions about how much of the story is already in the price. Recent coverage around Spectrum Brands Holdings has focused on its role in the Household Products space and how...